Vol. 23 No. 2 (2019)
ANESTHESIOLOGY & RESUSCITATION

Cardioprotective effect of lithium chloride on a rat model of myocardial infarction

PDF (Русский)
  • O. Grebenchikov,
  • A. Lobanov,
  • E. Shayhutdinova,
  • A. Kuzovlev,
  • A. Ershov,
  • V. Likhvantsev
O. Grebenchikov
Moscow Regional Research and Clinical Institute, Moscow, Russian Federation; Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Moscow, Russian Federation
A. Lobanov
Institute of General Pathology and Pathophysiology, Moscow, Russian Federation
E. Shayhutdinova
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russian Federation
A. Kuzovlev
Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Moscow, Russian Federation
A. Ershov
Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Moscow, Russian Federation; Sechenov First Moscow State Medical University, Moscow, Russian Federation
Bio
V. Likhvantsev
Moscow Regional Research and Clinical Institute, Moscow, Russian Federation; Sechenov First Moscow State Medical University, Moscow, Russian Federation
DOI: https://doi.org/10.21688/1681-3472-2019-2-43-49

Published 2019-10-15

Keywords

  • cardioprotection,
  • lithium chloride,
  • myocardial infarction

How to Cite

Grebenchikov, O., Lobanov, A., Shayhutdinova, E., Kuzovlev, A., Ershov, A., & Likhvantsev, V. (2019). Cardioprotective effect of lithium chloride on a rat model of myocardial infarction. Patologiya Krovoobrashcheniya I Kardiokhirurgiya, 23(2), 43–49. https://doi.org/10.21688/1681-3472-2019-2-43-49

Copyright (c) 2019 Grebenchikov O. A., Lobanov A. V., Shayhutdinova E. R., Kuzovlev A. N., Ershov A. V., Likhvantsev V. V.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

Aim. To investigate the cardioprotective effect of lithium chloride in vivo on a rat model of myocardial infarction.
Methods. Twelve male Sprague-Dawley rats were randomly divided into two groups of six, with both groups modelling cardiac ischaemia and subsequent reperfusion. At the start of reperfusion, 30 mg/kg of 4.2% lithium chloride solution was intravenously administered via a catheter to the test group and 0.5 ml/kg of saline solution was administered to the comparison group. A control group comprised sham-operated rats that were not injected with any drugs other than anaesthesia during making skin incision. At the end of each experiment, the total area of the risk zone and areas of the infarction zone and left ventricle were calculated for each animal using a double-staining technique with 2% methylene blue and 1% triphenyltetrazolium chloride. A further series of experiments using 15 male Sprague-Dawley rats (third group) was performed to assess the protein content of glycogen synthase-3β in myocardial tissue. The method was similar to that for the earlier experiments; however, at the end of the experiments, the hearts were removed and homogenised, following which the concentration of glycogen synthase-3β was determined using electrophoresis.
Results. The group treated with lithium chloride showed a significant decrease in the area of the infarction zone compared with the group treated with saline. The difference in the indices between the two groups was >26% (p < 0.05).
Conclusion. This study demonstrated that 30 mg/kg of 4.2% lithium chloride solution, administered at the onset of reperfusion, exerted a protective effect on cardiomyocytes in a rat model of myocardial infarction by reducing the area of the infarction zone compared with that in the control group. This effect was probably mediated by an almost two-fold increase in the content of the phosphorylated form of glycogen synthase-3β in the myocardium.

Received 23 June 2019. Revised 6 August 2019. Accepted 7 August 2019.

Funding: The study did not have sponsorship.

Conflict of interest: Authors declare no conflict of interest.

Author contributions
Conception and study design: A.N. Kuzovlev
Data collection and analysis: O.A. Grebenchikov
Statistical analysis: A.V. Ershov
Drafting the article: A.V. Lobanov, E.R. Shayhutdinova
Critical revision of the article: V.V. Likhvantsev
All authors approved final version to be published

PDF (Русский)

References

  1. Murry C.E., Jennings R.B., Reimer K.A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986;74(5):1124-36. PMID: 3769170 http://dx.doi.org/10.1161/01.cir.74.5.1124
  2. Chanoit G., Lee S., Xi J., Zhu M., McIntosh R.A., Mueller R.A., Norfleet E.A., Xu Z. Exogenous zinc protects cardiac cells from reperfusion injury by targeting mitochondrial permeability transition pore through inactivation of glycogen synthase kinase-3beta. Am J Physiol Heart Circ Physiol. 2008;295(3):H1227-H1233. PMID: 18660440 PMCID: PMC2544499 http://dx.doi.org/10.1152/ajpheart.00610.2008
  3. Li H., Lang X.E. Protein kinase C signaling pathway involvement in cardioprotection during isoflurane pretreatment. Mol Med Rep. 2015;11(4):2683-8. PMID: 25482108 http://dx.doi.org/10.3892/mmr.2014.3042
  4. Мороз В.В., Силачев Д.Н., Плотников Е.Ю., Зорова Л.Д., Певзнер И.Б., Гребенчиков О.А., Лихванцев В.В. Механизмы повреждения и защиты клетки при ишемии/реперфузии и экспериментальное обоснование применения препаратов на основе лития в анестезиологии. Общая реаниматология. 2013;9(1):63. https://doi.org/10.15360/1813-9779-2013-1-63 [Moroz V.V., Silachev D.N., Plotnikov E.Y., Zorova L.D., Pevzner I.B., Grebenchikov O.A., Likhvantsev V.V. Mechanisms of Cell Damage and Protection in Ischemia/Reperfusion and Experimental Rationale for the Use of Lithium-Based Preparations in Anesthesiology. General Reanimatology. 2013;9(1):63. (In Russ.) https://doi.org/10.15360/1813-9779-2013-1-63]
  5. Faghihi M., Mirershadi F., Dehpour A.R., Bazargan M. Preconditioning with acute and chronic lithium administration reduces ischemia/reperfusion injury mediated by cyclooxygenase not nitric oxide synthase pathway in isolated rat heart. Eur J Pharmacol. 2008;597(1-3):57-63. PMID: 18789320 http://dx.doi.org/10.1016/j.ejphar.2008.08.010
  6. Obame F.N., Plin-Mercier C., Assaly R., Zini R., Dubois-Randé J.L., Berdeaux A., Morin D. Cardioprotective effect of morphine and a blocker of glycogen synthase kinase 3 beta, SB216763 [3-(2,4-dichlorophenyl)-4(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione], via inhibition of the mitochondrial permeability transition pore. J Pharmacol Exp Ther. 2008;326(1):252-8. PMID: 18434587 http://dx.doi.org/10.1124/jpet.108.138008
  7. Gross E.R., Hsu A.K., Gross G.J. Opioid-induced cardioprotection occurs via glycogen synthase kinase beta inhibition during reperfusion in intact rat hearts. Circ Res. 2004;94(7):960-6. PMID: 14976126 http://dx.doi.org/10.1161/01.RES.0000122392.33172.09
  8. Gross E.R., Hsu A.K., Gross G.J. The JAK/STAT pathway is essential for opioid-induced cardioprotection: JAK2 as a mediator of STAT3, Akt, and GSK-3 beta. Am J Physiol Heart Circ Physiol. 2006;291(2): H827-34. PMID: 16517948 http://dx.doi.org/10.1152/ajpheart.00003.2006
  9. Nishihara M., Miura T., Miki T., Sakamoto J., Tanno M., Kobayashi H., Ikeda Y., Ohori K., Takahashi A., Shimamoto K. Erythropoietin affords additional cardioprotection to preconditioned hearts by enhanced phosphorylation of glycogen synthase kinase-3 beta. Am J Physiol Heart Circ Physiol. 2006;291(2): H748-55. PMID: 16565311 http://dx.doi.org/10.1152/ajpheart.00837.2005
  10. Park S.S., Zhao H., Mueller R.A., Xu Z. Bradykinin prevents reperfusion injury by targeting mitochondrial permeability transition pore through glycogen synthase kinase 3beta. J Mol Cell Cardiol. 2006;40(5):708-16. PMID: 16516918 http://dx.doi.org/10.1016/j.yjmcc.2006.01.024
  11. Forster K., Paul I., Solenkova N., Staudt A., Cohen M.V., Downey J.M., Felix S.B., Krieg T. NECA at reperfusion limits infarction and inhibits formation of the mitochondrial permeability transition pore by activating p70S6 kinase. Basic Res Cardiol. 2006;101(4):319-26. PMID: 16604438 http://dx.doi.org/10.1007/s00395-006-0593-4
  12. Kovacs K., Toth A., Deres P., Kalai T., Hideg K., Gallyas F. Jr., Sumegi B. Critical role of PI3-kinase/Akt activation in the PARP inhibitor induced heart function recovery during ischemia-reperfusion. Biochem Pharmacol. 2006;71(4):441-52. PMID: 16337154 http://dx.doi.org/10.1016/j.bcp.2005.05.036
  13. Mio Y., Shim Y.H., Richards E., Bosnjak Z.J., Pagel P.S., Bienengraeber M. Xenon preconditioning: the role of prosurvival signaling, mitochondrial permeability transition and bioenergetics in rats. Anesth Analg. 2009;108(3):858-866. PMID: 19224794 PMCID: PMC2748301 http://dx.doi.org/10.1213/ane.0b013e318192a520
  14. Kamada N., Kanaya N., Hirata N., Kimura S., Namiki A. Cardioprotective effects of propofol in isolated ischemia-reperfused guinea pig hearts: role of KATP channels and GSK-3beta. Can J Anaesth. 2008;55(9):595-605. PMID: 18840589 http://dx.doi.org/10.1007/BF03021433
  15. Feng J., Lucchinetti E., Ahuja P., Pasch T., Perriard J.C., Zaugg M. Isoflurane postconditioning prevents opening of the mitochondrial permeability transition pore through inhibition of glycogen synthase kinase 3beta. Anesthesiology. 2005;103(5):987-95. PMID: 16249673 http://dx.doi.org/10.1097/00000542-200511000-00013
  16. Juhaszova M., Zorov D.B., Kim S.H., Pepe S., Fu Q., Fishbein K.W., Ziman B.D., Wang S., Ytrehus K., Antos C.L., Olson E.N., Sollott S.J. Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest. 2004;113(11):1535-49. PMID: 15173880 PMCID: PMC419483 http://dx.doi.org/10.1172/JCI19906
  17. Buchholz B., Kelly J., Muñoz M., Bernatené E.A., Méndez Diodati N., González Maglio D.H., Dominici F.P., Gelpi R.J. Vagal stimulation mimics preconditioning and postconditioning of ischemic myocardium in mice by activating different protection mechanisms. Am J Physiol Heart Circ Physiol. 2018;314(6):H1289-H1297. PMID: 29631370 http://dx.doi.org/10.1152/ajpheart.00286.2017
  18. Likhvantsev V.V., Landoni G., Levikov D.I., Grebenchikov O.A., Skripkin Y.V., Cherpakov R.A. Sevoflurane Versus Total Intravenous Anesthesia for Isolated Coronary Artery Bypass Surgery With Cardiopulmonary Bypass: A Randomized Trial. J Cardiothorac Vasc Anesth. 2016;30(5):1221-7. PMID: 27431595 http://dx.doi.org/10.1053/j.jvca.2016.02.030
  19. Landoni G, Greco T, Biondi-Zoccai G, Nigro Neto C, Febres D, Pintaudi M, Pasin L, Cabrini L, Finco G, Zangrillo A. Anaesthetic drugs and survival: a Bayesian network meta-analysis of randomized trials in cardiac surgery. Br J Anaesth. 2013;111(6):886-96. PMID: 23852263 http://dx.doi.org/10.1093/bja/aet231
  20. Mozaffari M.S., Schaffer S.W. Effect of pressure overload on cardioprotection of mitochondrial KATP channels and GSK-3beta: interaction with the MPT pore. Am J Hypertens. 2008;21(5):570-5. PMID: 18437149 http://dx.doi.org/10.1038/ajh.2008.25
  21. Taliyan R., Ramagiri S. Delayed neuroprotection against cerebral ischemiareperfusion injury: putative role of BDNF and GSK-3β. J Recept Signal Transduct Res. 2016;36(4):402-10. PMID: 26554621 http://dx.doi.org/10.3109/10799893.2015.1108338
  22. Talab S.S., Elmi A., Emami H., Nezami B.G., Assa S., Ghasemi M., Tavangar S.M., Dehpour A.R. Protective effects of acute lithium preconditioning against renal ischemia/reperfusion injury in rat: role of nitric oxide and cyclooxygenase systems. Eur J Pharmacol. 2012;681(1-3):94-9. PMID: 22342279 http://dx.doi.org/10.1016/j.ejphar.2012.01.042
  23. Селье Г. Профилактика некрозов сердца химическими средствами (пер. с англ.). М.: Медгиз, 1961. 208 с. [Selye H. The Chemical Prevention of Cardiac Necroses. New York: Ronald Press Co; 1958. 235 р.]
  24. Wu Q.L., Shen T., Ma H., Wang J.K. Sufentanil postconditioning protects the myocardium from ischemia-reperfusion via PI3K/Akt-GSK-3β pathway. J Surg Res. 2012;178(2):563-70. PMID: 22727941 http://dx.doi.org/10.1016/j.jss.2012.05.081
  25. Zhang Y., Irwin M.G., Wong T.M. Remifentanil preconditioning protects against ischemic injury in the intact rat heart. Anesthesiology. 2004;101(4):918-23. PMID: 15448525 http://dx.doi.org/10.1097/00000542-200410000-00017
  26. Barillas R., Friehs I., Cao-Danh H., Martinez J.F., del Nido P.J. Inhibition of glycogen synthase kinase-3beta improves tolerance to ischemia in hypertrophied hearts. Ann Thorac Surg. 2007;84(1):126-33. PMID: 17588398 PMCID: PMC3444259 http://dx.doi.org/10.1016/j.athoracsur.2007.02.015
  27. Лихванцев В.В., Гребенчиков О.А., Борисов К.Ю., Шайбакова В.Л., Шапошников А.А., Черпаков Р.А., Шмелева Е.В. Механизмы фармакологического прекондиционирования мозга и сравнительная эффективность препаратов — ингибиторов гликоген-синтетазы-киназы — 3 бета прямого и непрямого действия (экспериментальное исследование). Общая реаниматология. 2012;8(6):37-42. https://doi.org/10.15360/1813-9779-2012-6-37 [Likhvantsev V.V., Grebenchikov O.A., Borisov K.Y., Shaibakova V.L., Shaposhnikov A.A., Cherpakov R.A., Shmeleva E.V. The Mechanisms of Pharmacological Preconditioning of the Brain and the Comparative Efficacy of the Drugs — Direct- and Indirect-Acting Glycogen Synthase Kinase-3β Inhibitors: Experimental Study. General Reanimatology. 2012;8(6):37-42. (In Russ.) https://doi.org/10.15360/1813-9779-2012-6-37]